[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort

Catalyst Pharmaceuticals (CPRX) reports first-quarter 2026 earnings on May 11 after market close, with analysts expecting $0.58 per share on revenue of approximately $147 million. The central question: can the rare disease specialist sustain momentum from its flagship LEMS treatment Firdapse while navigating patent headwinds for Fycompa and scaling its newer Agamree franchise? With the stock trading near 52-week highs and a perfect four-quarter beat streak behind it, investors will scrutinize whether CPRX can deliver another upside surprise or if estimates have finally caught up to reality.

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare neuromuscular, neurological, and...

Fundamentals

See More
  • Market Capitalization, $K 3,811,078
  • Shares Outstanding, K 122,346
  • Annual Sales, $ 588,990 K
  • Annual Income, $ 214,330 K
  • EBIT $ 295 M
  • EBITDA $ 333 M
  • 60-Month Beta 0.72
  • Price/Sales 6.47
  • Price/Cash Flow 10.66
  • Price/Book 4.01

Options Overview Details

View History
  • Implied Volatility 13.88% (-0.54%)
  • Historical Volatility 41.01%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 120.40% on 10/14/25
  • IV Low 13.88% on 05/08/26
  • Expected Move (DTE 5) 1.06 (3.41%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 670
  • Volume Avg (30-Day) 1,113
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 14,446
  • Open Int (30-Day) 11,162
  • Expected Range 30.09 to 32.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.58
  • Number of Estimates 2
  • High Estimate $0.59
  • Low Estimate $0.57
  • Prior Year $0.63
  • Growth Rate Est. (year over year) -7.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.69 +26.16%
on 04/13/26
32.56 -4.33%
on 04/27/26
+5.84 (+23.07%)
since 04/08/26
3-Month
22.16 +40.57%
on 03/20/26
32.56 -4.33%
on 04/27/26
+6.71 (+27.45%)
since 02/06/26
52-Week
19.05 +63.52%
on 09/25/25
32.56 -4.33%
on 04/27/26
+8.39 (+36.86%)
since 05/08/25

Most Recent Stories

More News
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.15 (-0.05%)
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals...

CPRX : 31.15 (-0.05%)
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.15 (-0.05%)
Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACR : 22.60 (-0.57%)
TBRG : 25.83 (+0.19%)
CPRX : 31.15 (-0.05%)
MDV : 17.97 (+0.96%)
CPRX's Rare Disease Portfolio May Finally Be Too Concentrated for Comfort

Barchart Research What to Expect from CPRX Earnings CPRX Generated May 8, 2026 Current Price $31.15 EPS Estimate $$0.58 Consensus Rating Strong Buy Average Move 5.18% CPRX's Rare Disease Portfolio May...

CPRX : 31.15 (-0.05%)
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 31.15 (-0.05%)
Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE   , May 7, 2026 /PRNewswire/ -- Ademi LLP is investigating Catalyst (NASDAQ: CPRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

CPRX : 31.15 (-0.05%)
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

CPRX : 31.15 (-0.05%)
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla.,...

CPRX : 31.15 (-0.05%)
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026

CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 31.15 (-0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 31.28
2nd Resistance Point 31.24
1st Resistance Point 31.20
Last Price 31.15
1st Support Level 31.12
2nd Support Level 31.08
3rd Support Level 31.04

See More

52-Week High 32.56
Last Price 31.15
Fibonacci 61.8% 27.40
Fibonacci 50% 25.81
Fibonacci 38.2% 24.21
52-Week Low 19.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.